EKF Diagnostics Holdings (GB:EKF) has released an update.
EKF Diagnostics Holdings PLC reports a significant uptick in earnings and cash flow for the first half of 2024, with a 20% year-on-year growth in adjusted EBITDA and strong sales, particularly in its Life Sciences division’s fermentation business. The company’s strategic refocusing on higher margin products and cost stabilization has paid off, leading to a robust financial position with expectations to meet full year market forecasts.
For further insights into GB:EKF stock, check out TipRanks’ Stock Analysis page.
